478 related articles for article (PubMed ID: 17108811)
1. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
2. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
3. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
[TBL] [Abstract][Full Text] [Related]
4. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
[TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.
Tornio A; Vakkilainen J; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2015 Aug; 25(8):382-7. PubMed ID: 26020121
[TBL] [Abstract][Full Text] [Related]
6. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
9. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.
Wagner JB; Abdel-Rahman S; Van Haandel L; Gaedigk A; Gaedigk R; Raghuveer G; Kauffman R; Leeder JS
J Clin Pharmacol; 2018 Jun; 58(6):823-833. PubMed ID: 29469964
[TBL] [Abstract][Full Text] [Related]
10. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
[TBL] [Abstract][Full Text] [Related]
11. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
[TBL] [Abstract][Full Text] [Related]
12. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
16. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
Igel M; Arnold KA; Niemi M; Hofmann U; Schwab M; Lütjohann D; von Bergmann K; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2006 May; 79(5):419-26. PubMed ID: 16678544
[TBL] [Abstract][Full Text] [Related]
17. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
Zhang W; He YJ; Han CT; Liu ZQ; Li Q; Fan L; Tan ZR; Zhang WX; Yu BN; Wang D; Hu DL; Zhou HH
Br J Clin Pharmacol; 2006 Nov; 62(5):567-72. PubMed ID: 16796707
[TBL] [Abstract][Full Text] [Related]
18. Influence of
Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
[TBL] [Abstract][Full Text] [Related]
19. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
20. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
